+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 1
Phase 2
Age: 18Years +
MALE
ID07259213

Phase 12a Study of 161Tb-RAD402, a Radiolabeled Antibody Targeting Prostate-Specific Antigen, in Men With Castration-Resistant Prostate Cancer

Led by Radiopharm Theranostics, Ltd · Updated on 2026-04-01

73

Participants Needed

2

Research Sites

17 weeks

Total Duration

AI-Summary

What This Trial Is About

Researchers are evaluating 161Tb-RAD402, a radiolabeled monoclonal antibody targeting free prostate-specific antigen, in men with castration-resistant prostate cancer CRPC. This Phase 12a study aims to assess the safety, tolerability, whole-body distribution, pharmacokinetics, radiation dosimetry, and preliminary anti-tumor activity of 161Tb-RAD402. The study also seeks to determine the maximum tolerated dose and recommended Phase 2 dose for this treatment in participants with locally advanced or metastatic CRPC who have progressed after prior therapies. The study has two parts Phase 1 involves dose escalation to establish safety and dosing using a Bayesian Optimal Interval design Phase 2a is a dose expansion phase at the recommended dose to confirm safety and evaluate preliminary anti-tumor effects using a Bayesian beta-binomial design based on prostate-specific antigen PSA response. Participants receive 161Tb-RAD402 administered at treatment doses, and the study is an open-label, single-arm trial. Participants will go through a screening period, followed by treatment and imaging periods, and then safety and long-term follow-up. Researchers will monitor adverse events, pharmacokinetics, biodistribution, radiation dosimetry, and biochemical responses including PSA levels. Follow-up and assessments are conducted up to 30 weeks post-treatment to evaluate tumor activity and safety outcomes, with ongoing monitoring for side effects and treatment tolerability.

CONDITIONS

Brief Title

A Study of Terbium 161 (161Tb)-RAD402 in Participants With CRPC

Research Team

D

Dimitris Voliotis, MD

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here